China’s health care companies rush to raise capital during fight against coronavirus pandemic
- Health care firms have raised US$7.9 billion in Hong Kong, Shanghai and Shenzhen so far this year, up from US$2.7 billion a year ago
- More biotech companies are pursuing dual listings in Hong Kong and mainland markets,says 3H Health Investment
Health care companies are raising capital at a faster clip this year in Hong Kong and mainland China, encouraged by supportive government policies and investors clamouring to participate in the sector’s growth.
The companies are riding on tailwinds created by increased government spending in the fight to contain the coronavirus pandemic, the race to find a vaccine and rising consumer adoption of technologies designed to supplement China’s overcrowded hospitals, industry experts said during a South China Morning Post webinar.
“This crisis has highlighted the gap in the quality of health care and the equipment between China and the developed world,” said John Woods, Credit Suisse’s Asia-Pacific chief investment officer, during the webinar on “Investment Opportunities in China’s Healthcare Sector after Covid-19”.
